2. Antibody-drug Conjugate/ADC Related Cytoskeleton
  3. Peptide-Drug Conjugates (PDCs) Integrin
  4. BGC0222

BGC0222 是一种新型 Irinotecan (HY-16562) 原药。BGC0222 作为一种 PEG-cRGD 偶联的 Irinotecan (HY-16562) 衍生物，可缓慢、稳定地释放 Irinotecan (HY-16562)。BGC0222 与 αVβ3 靶点结合，其 IC50 值为 4.25 μM，针对 αVβ5 的 IC50 为 58.7 μM。BGC0222 可诱导血管新生。BGC0222 在多种肿瘤中表现出良好的抗肿瘤活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

BGC0222

BGC0222 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

BGC0222 相关抗体

Top Publications Citing Use of Products

查看 Integrin 亚型特异性产品:

查看所有亚型
αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors[1].

体外研究
(In Vitro)

BGC0222 (72 h) 与 Irinotecan (HY-16562) 和 NKTR-102 相比，对 HT29、MIA PaCa-2 和 MCF-7 肿瘤细胞具有更好的抗增殖活性，IC50 分别为 1.83 μM、3.95 μM 和 0.68 μM[1]。
BGC0222 (40 μM) 显示出良好的血管生成活性，血管长度达 1930 mm (CAM 血管生成试验)[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

BGC0222 相关抗体:
体内研究
(In Vivo)

BGC0222 (20-60 mg/kg，静脉注射，每 4 天或每周 1 次，共 3 次) 在 HT-29、MIA PaCa-2、NCI-H446、U-87 MG 和 MDA-MB-231 异种移植裸鼠中表现出显著的抗增殖活性，其 RTV 和 T/C 值均低于 Irinotecan[1]。
BGC0222 (30-90 mg/kg，静脉注射，每周一次，为期 28 天) 在 Sprague-Dawley 大鼠体内的安全性irinotecan 相比有所改善，最大耐受剂量 (MTD) 分别为 90 mg/kg和低于 60 mg/kg[1]。
BGC0222 (20-80 mg/kg，静脉注射，单次) 在 Sprague-Dawley 大鼠体内缓慢而稳定地释放Irinotecan[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: HT-29, MIA PaCa-2, NCI-H446, U-87 MG and MDA-MB-231 xenograft female Balb/c nude mice (HT-29, 4 × 106; MIA PaCa-2, 5 × 106; NCI-H446, 8 × 106; U-87 MG,4 × 106; MDA-MB-231, 3 × 106)[1]
Dosage: 20 mg/kg (MIA PaCa-2, NCI-H446, MDA-MB-231); 40 mg/kg (HT-29); 60 mg/kg (U-87 MG)
Administration: Intravenous injection (i.v.), every 4 days (HT-29 and MDA-MB-231) or once a week (MIA PaCa-2, NCI-H446 and U-87 MG), 3 times
Result: Exhibited remarkable antiproliferation activity in the HT-29, MIA PaCa-2, NCI-H446, U-87 MG and MDA-MB-231 xenograft nude mice.
Exhibited that T/C values of BGC0222 for days 12, 15, 18, 22, 25, 29 and 32 were determined to be 100%, 88.8%, 57.0%, 27.6%, 16.9%, 9.87% and 9.21%, while that of irinotecan were found to be 100%, 103%, 93.1%, 75.1%, 68.8%, 60.6%, 71.1% in the HT-29 xenograft nude mice, respectively.
Showed that the RTV values of BGC0222 were much lower than that of irinotecan and NKTR-102 when the average tumor size reached approximately 100–300 mm3 (after day 12) in the HT-29 xenograft nude mice.
分子量

26927.36

Formula

C1241H2276N64O552
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

BGC0222 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BGC0222BGC 0222BGC-0222Peptide-Drug Conjugates (PDCs)IntegrinHT29MIA PaCa-2MCF-7NCI-H446AntiproliferationBalb/c.Inhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
BGC0222
目录号：
HY-P10783
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z